[1] MOLLER H J.Soluble CD163[J].Scand J Clin Lab Invest,2012,72(1):1-13.
[2] ZHANG X L,GUO Y F,SONG Z X,et al.Vitamin D prevents podocyte injury via regulation of macrophage M1/M2 phenotype in diabetic nephropathy rats[J].Endocrinology,2014,155(12):4939-4950.
[3] 陈灏珠,钟南山,陆再英.内科学[M].北京:人民卫生出版社,2013:735-736.
[4] CAROLAN E,HOGAN A E,CORRIGAN M,et al.The impact of childhood obesity on inflammation,innate immune cell frequency,and metabolic microRNA expression[J].J Clin Endocrinol Metab,2014,99(3):E474-478.
[5] FJELDBORG K,CHRISTIANSEN T,BENNETZEN M,et al.The macrophage-specific serum marker,soluble CD163,is increased in obesity and reduced after dietary-induced weight loss[J].Obesity(Silver Spring),2013,21(12):2437-2443.
[6] SORENSEN L P,PARKNER T,SONDERGAARD E,et al.Visceral obesity is associated with increased soluble CD163 concentration in men with type 2 diabetes mellitus[J].Endocr Connect,2015,4(1):27-36.
[7] FINK L N,OBERBACH A,COSTFORD S R,et al.Expression of anti-inflammatory macrophage genes within skeletal muscle correlates with insulin sensitivity in human obesity and type 2 diabetes[J].Diabetologia,2013,56(7):1623-1628.
[8] HATTORI A,TAKEMOTO M,TOKUYAMA H,et al.Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163,a marker for activated macrophage,in individuals with type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2017,126:138-143.
[9] MORENO P R,PURUSHOTHAMAN M,PURUSHOTHAMAN K R.Plaque neovascularization:defense mechanisms,betrayal,or a war in progress[J].Ann N Y Acad Sci,2012,1254:7-17.
[10] FADINI G P,de KREUTZENBERG S V,BOSCARO E,et al.An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy[J].Diabetologia,2013,56(8):1856-1866.
[11] KLESSENS C Q F,ZANDBERGEN M,WOLTERBEEK R,et al.Macrophages in diabetic nephropathy in patients with type 2 diabetes[J].Nephrol Dial Transplant,2017,32(8):1322-1329.
[12] 邵红,关红,谢立凯,等.2型糖尿病肾病患者sCD163检测的临床意义[J].中国实验诊断学,2015,19(11):1961-1962.
[13] YOSHIDA S,KOBAYASHI Y,NAKAMA T,et al.Increased expression of M-CSF and IL-13 in vitreous of patients with proliferative diabetic retinopathy:implications for M2 macrophage-involving fibrovascular membrane formation[J].Br J Ophthalmol,2015,99(5):629-634.
[14] KOBAYASHI Y,YOSHIDA S,NAKAMA T,et al.Overexpression of CD163 in vitreous and fibrovascular membranes of patients with proliferative diabetic retinopathy:possible involvement of periostin[J].Br J Ophthalmol,2015,99(4):451-456.
[15] KALLESTRUP M,MOLLER H J,TANKISI H,et al.Soluble CD163 levels are elevated in cerebrospinal fluid and serum in people with Type 2 diabetes mellitus and are associated with impaired peripheral nerve function[J].Diabet Med,2015,32(1):54-61.
[16] SHIRAISHI D,FUJIWARA Y,KOMOHARA Y,et al.Glucagon-like peptide-1(GLP-1) induces M2 polarization of human macrophages via STAT3 activation[J].Biochem Biophys Res Commun,2012,425(2):304-308.
[17] SHAH Z,KAMPFRATH T,DEIULⅡS J A,et al.Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis[J].Circulation,2011,124(21):2338-2349.
[18] XU L,NAGATA N,NAGASHIMADA M,et al.SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice[J].E Bio Medicine,2017,20:137-149.
[19] JAIKUMKAO K,PONGCHAIDECHA A,CHATSUDTHIPONG V,et al.The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes[J].Biomed Pharmacother,2017,94:176-187.
[20] SPORRER D,WEBER M,WANNINGER J,et al.Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity[J].Eur J Clin Invest,2009,39(8):671-679. |
